verywellhealth17h
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon
Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...
Rolling Out10d
5 ways this cancer drug could revolutionize Alzheimer’s treatment
Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.
Could Alzheimer’s treatment drugs be the next big investor opportunity after obesity pills?
The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...
New dementia tool predicts when symptoms will start: ‘Would you want to know?’
Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...
Dementia risk for people 55 and older has doubled, new study finds
Dementia cases in the U.S. are expected to double by 2060, with an estimated one million people diagnosed per year, according ...
Why Alzheimer’s scientists are rethinking the amyloid hypothesis
Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...
Rolling Out6d
Alzheimer’s toll on Black Americans
Delve into the challenges Black Americans face with Alzheimer’s and the urgent need for better prevention, care, and ...
Alzheimer’s disease market expected to reach $19.3bn across the 8MM by 2033
While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...